Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
暂无分享,去创建一个
J. Kuriyan | J. Bertino | W. Bornmann | T. Schindler | M. Young | B. Nagar | D. Veach | B. Clarkson | A. Strife | C. Lambek | D Wisniewski | Chongyuan Liu
[1] John Kuriyan,et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.
[2] M. Debiec‐Rychter,et al. Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. , 2001, Cancer genetics and cytogenetics.
[3] Y. Ma,et al. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.
[4] J. Bennett,et al. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. , 2001, Leukemia research.
[5] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[6] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.
[7] B. Druker,et al. STI571: A gene product-targeted therapy for leukemia , 2001, Current oncology reports.
[8] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[9] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[10] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[11] F. Rossi,et al. Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease , 2001, British journal of haematology.
[12] G. Krystal. Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[13] R. V. van Etten,et al. c-Abl Has High Intrinsic Tyrosine Kinase Activity That Is Stimulated by Mutation of the Src Homology 3 Domain and by Autophosphorylation at Two Distinct Regulatory Tyrosines* , 2000, The Journal of Biological Chemistry.
[14] O. Witte,et al. Consequences of BCR‐ABL Expression within the Hematopoietic Stem Cell in Chronic Myeloid Leukemia , 2000, Stem cells.
[15] M. Zucchetti,et al. Role of (cid:1) 1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL + Leukemic Cells to the Abl Inhibitor STI571 , 2000 .
[16] H. D. Showalter,et al. Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. , 2000, Biochemical pharmacology.
[17] B. Druker,et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[18] P. Seeburg,et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.
[19] S. Honsawek,et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] J. Melo,et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.
[21] Matthew B. Wilson,et al. Transformation of Myeloid Leukemia Cells to Cytokine Independence by Bcr-Abl Is Suppressed by Kinase-defective Hck* , 2000, The Journal of Biological Chemistry.
[22] R. Jove,et al. The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. , 2000, Cancer research.
[23] S. Jhanwar,et al. Characterization of two novel sublines established from a human megakaryoblastic leukemia cell line transfected with p210BCR-ABL , 2000 .
[24] M. Varella‐Garcia,et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. , 2000, Blood.
[25] S. Jhanwar,et al. Characterization of two novel sublines established from a human megakaryoblastic leukemia cell line transfected with p210(BCR-ABL). , 2000, Leukemia research.
[26] J. Griffin,et al. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. , 2000, Blood.
[27] G. Mcmahon,et al. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. , 1999, Journal of medicinal chemistry.
[28] N. Rosen,et al. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. , 1999, Cancer research.
[29] H. Lodish,et al. BCR-ABL and v-SRC tyrosine kinase oncoproteins support normal erythroid development in erythropoietin receptor-deficient progenitor cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[30] A. Kazlauskas,et al. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. , 1999, Genes & development.
[31] P. Marks,et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. , 1999, Cancer research.
[32] H. Erdjument-Bromage,et al. A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. , 1999, Blood.
[33] Jon C. Aster,et al. Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 bcr/abl-Transduced Bone Marrow , 1998 .
[34] L. To,et al. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells. , 1998, Blood.
[35] D. Boschelli,et al. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors. , 1998, Journal of medicinal chemistry.
[36] G. Mcmahon,et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. , 1998, Journal of medicinal chemistry.
[37] P. Pandolfi,et al. Molecular Cloning and Characterization of p56 dok-2 Defines a New Family of RasGAP-binding Proteins* , 1998, The Journal of Biological Chemistry.
[38] T. Hunter. The role of tyrosine phosphorylation in cell growth and disease. , 1998, Harvey lectures.
[39] M. Warmuth,et al. The Src Family Kinase Hck Interacts with Bcr-Abl by a Kinase-independent Mechanism and Phosphorylates the Grb2-binding Site of Bcr* , 1997, The Journal of Biological Chemistry.
[40] Ravi Salgia,et al. The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors , 1997, Oncogene.
[41] A. Strife,et al. New understanding of the pathogenesis of CML: a prototype of early neoplasia , 1997, Leukemia.
[42] A. Doherty,et al. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. , 1997, Journal of medicinal chemistry.
[43] R. Kobayashi,et al. p62 dok : A Constitutively Tyrosine-Phosphorylated, GAP-Associated Protein in Chronic Myelogenous Leukemia Progenitor Cells , 1997, Cell.
[44] M. Warmuth,et al. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. , 1996, Cancer research.
[45] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[46] A. Strife,et al. c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia. , 1996, Leukemia.
[47] T. Meyer,et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.
[48] N. Heisterkamp,et al. Crkl Is Complexed with Tyrosine-phosphorylated Cbl in Ph-positive Leukemia (*) , 1995, The Journal of Biological Chemistry.
[49] A. Levitzki,et al. Tyrosine kinase inhibition: an approach to drug development. , 1995, Science.
[50] N. Heisterkamp,et al. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. , 1994, Blood.
[51] B. Clarkson,et al. A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blast populations. , 1994, Leukemia.
[52] R. Salgia,et al. Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. , 1994, The Journal of biological chemistry.
[53] J. Dick,et al. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. , 1994, Blood.
[54] O. Witte,et al. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence , 1993, Molecular and cellular biology.
[55] Z. Darżynkiewicz,et al. Characterization of lineage-negative blast subpopulations derived from normal and chronic myelogenous leukemia bone marrows and determination of their responsiveness to human c-kit ligand. , 1993, Cancer research.
[56] N. Rosenberg,et al. Lymphoid cells transformed by Abelson virus require the v-abl protein-tyrosine kinase only during early G1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[57] L. Cantley,et al. Oncogenes and signal transduction , 1991, Cell.
[58] Joseph Schlessinger,et al. Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.
[59] G. Daley,et al. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.
[60] T. Hunter. 6 Oncogene Products in the Cytoplasm: The Protein Kinases , 1989 .
[61] H. Bourne,et al. 4 Signal Transduction and Intracellular Messengers , 1989 .
[62] R. Weinberg. Oncogenes and the molecular origins of cancer , 1989 .
[63] B. Clarkson,et al. Discordant maturation as the primary biological defect in chronic myelogenous leukemia. , 1988, Cancer research.
[64] L. Naldini,et al. Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells , 1986, Molecular and cellular biology.
[65] E. Canaani,et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia , 1985, Nature.
[66] Susan M. Watanabe,et al. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity , 1984, Cell.
[67] J. Stephenson,et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 , 1984, Cell.
[68] J. Stephenson,et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia , 1983, Nature.
[69] T. Papayannopoulou,et al. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. , 1977, The American journal of medicine.
[70] J. Rowley. A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.
[71] T. Caspersson,et al. Identification of the Philadelphia chromosome as a number 22 by quinacrine mustard fluorescence analysis. , 1970, Experimental cell research.